Skip to main content
. 2020 Jun 23;64(7):e02584-19. doi: 10.1128/AAC.02584-19

TABLE 3.

Pharmacokinetic estimates for ertapenem across the study phases

Phasea Mean value (SD)b
Total drug concn data
Free drug concn data
AUC0–24 (mg · h/liter) kel (h−1) V (liters) CL (liters/h) AUC0–24 (mg · h/liter) kel (h−1) V (liters) CL (liters/h)
1 26.9 (3.2) B 0.9 (0.3) 28.7 (7.3) B 25.0 (3.7) B 16.0 (2.3) B 1.2 (0.4) 38.4 (9.4) 42.3 (7.5) B
2 24.8 (7.4) C 1.2 (0.4) 26.8 (11.2) C 28.8 (8.2) C 14.5 (4.7) C 1.2 (0.4) 42.1 (14.2) 49.9 (15.2) C
3 78.0 (16.1) 0.8 (0.1) 10.6 (1.8) 8.9 (2.2) 25.5 (6.4) 0.9 (0.2) 30.5 (7.8) 27.6 (7.4)
a

Phase 1, normoalbuminemia; phase 2, hypoalbuminemia; phase 3, albumin replacement.

b

AUC0–24, area under the concentration-time curve during a 24-h period; CL, clearance; kel, elimination constant; V, volume of distribution; B, significant difference (P < 0.05) between phases 1 and 3; C, significant difference (P < 0.05) between phases 2 and 3.